Eloxx Pharmaceuticals clinical trials we track

Check company identity source

Phase 2 3 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters
A Study of ELX-02 in Patients With Alport Syndrome

NCT05448755 · Eloxx Pharmaceuticals, Inc.

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: The incidence and characteristics of adverse events. After: Measure: Number of Participants With Adverse Events Associated With Administration of 0.75 mg/kg of ELX-02 Once Daily.

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 8 participants (planned). After: 3 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 30 May 2023. After: 11 Sep 2023.

Recruitment status changed

Before: Recruiting. After: Completed.

Check registry source